X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): VLX-1005
Therapeutic Area: Hematology Product Name: VLX-1005
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Hatteras Venture
Deal Size: $16.6 million Upfront Cash: Undisclosed
Deal Type: Series A Financing June 16, 2021
Details:
The Series A financing, will support Veralox's efforts to advance the development program for its lead product candidate VLX-1005 for the treatment of heparin-induced thrombocytopenia (HIT).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CAN106
Therapeutic Area: Hematology Product Name: CAN106
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: WuXi Biologics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 10, 2021
Details:
CAN106 is a recombinant human monoclonal antibody that specifically binds to and neutralizes C5 and is intended to prevent the formation of membrane attack complexes on red blood cell surfaces, thereby reducing cell lysis and other symptoms associated with PNH.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): OMS906
Therapeutic Area: Hematology Product Name: OMS906
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 16, 2020
Details:
The presentation included data demonstrating that a single dose of OMS906 in an animal study demonstrated a decrease of mature CFD and an increase and accumulation in pro-CFD levels that remained detectable for more than three weeks.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
